Physician profile
Cong Ran
NPI 1194110700
$1,728.88
in general payments reported to CMS, 2019-2025
11 companies · $525 in 2025
The $525 reported for 2025 was more than what 76% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.46 · 2021: $533 · 2022: $116 · 2024: $529 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $430.20 | 2024-2025 | Scopis Ent, Medline Industries, INC. |
| Allergan, INC. | $390.34 | 2021-2022 | |
| Galderma Laboratories, L.P. | $238.06 | 2021-2024 | |
| Medtronic, INC. | $148.24 | 2025 | Ligasure |
| Acclarent, INC | $133.00 | 2024 | Trudi Nav Cable, Relieva Tract |
| Neurent Medical Limited | $119.99 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Revance Therapeutics, INC. | $116.55 | 2024 | Daxi |
| Merz North America, INC. | $50.66 | 2020-2021 | |
| Integra Lifesciences Corporation | $49.58 | 2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Abbvie INC. | $28.36 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $23.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cong Ran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.